Having trouble accessing articles? Reset your cache.

Arzerra ofatumumab: Development discontinued

The partners said GlaxoSmithKline will discontinue development of IV ofatumumab for autoimmune indications to instead focus on a subcutaneous

Read the full 198 word article

User Sign In

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE